Cytochromes P450: A structure-based summary of biotransformations using representative substrates

Drug Metabolism Reviews

Volumn 40, Issue 1, 2008, Pages 1-100

  Brown, Caitlin M ^a   Reisfeld, Brad ^a,b   Mayeno, Arthur N ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b Department of Mechanical Engineering   (United States)

Author keywords

Biotransformation; CYP; Cytochrome P450; Drug; Isozyme; Metabolism; Toxicant; Xenobiotics

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ACETANILIDE; ALCOHOL; ALVOSULFON; AMFEBUTAMONE; AMITRIPTYLINE; AMODIAQUINE; AMPHETAMINE; ANILINE; APRINDINE; ATOMOXETINE; BEATROLOL; BUFURALOL; CARBAMAZEPINE; CARVEDILOL; CELECOXIB; CHLORPROMAZINE; CHLORZOXAZONE; CISAPRIDE; CLOZAPINE; CODEINE; CYTOCHROME P450; DEBRISOQUINE; DIAZEPAM; DICLOFENAC; DOLASETRON MESILATE; DRONABINOL; ERYTHROMYCIN; ESOMEPRAZOLE; FELODIPINE; FLUOXETINE; FURAN; HALOPERIDOL; IBUPROFEN; IMIPRAMINE; ISOENZYME; LAURIC ACID; LIDOCAINE; LORATADINE; METHAMPHETAMINE; METOPROLOL; METOPROLOL TARTRATE; MEXILETINE; MIANSERIN; MIDAZOLAM MALEATE; MIFEPRISTONE; N METHYLFORMAMIDE; NAPROXEN; NELFINAVIR; OMEPRAZOLE; PACLITAXEL; PARACETAMOL; PERPHENAZINE; PERTONAL; PHENACETIN; PHENAMINE; PHENOBARBITAL; PROGUANIL; PROSORB D; QUINIDINE SULFATE; RAPAMYCIN; RETINOIC ACID; SELEGILINE; SERATRODAST; SIMVAST; SIMVASTATIN; TACRINE; TACROLIMUS; TAMOXIFEN; TAMOXIFEN CITRATE; TENIPOSIDE; TOLUENE; TRICHLOROETHYLENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; WARFARIN; ZILEUTON;

BIOTRANSFORMATION; CATALYSIS; CHEMICAL REACTION; CHEMICAL STRUCTURE; HUMAN; PHARMACOPHORE; PROTEIN STRUCTURE; REVIEW; TAXONOMY;

ANIMALS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOENZYMES; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; XENOBIOTICS;

EID: 38949204984     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.1080/03602530701836662     Document Type: Review

References (45)

1. Cerny, M. A., Hanzlik, R. P. (2006). Cytochrome P450-catalyzed oxidation of N-benzyl-N-cyclopropylamine generates both cyclopropanone hydrate and 3-hydroxypropionaldehyde via hydrogen abstraction, not single electron transfer. J. Amer. Chem. Soc. 128:3346-3354.
2. Constantino, L., Rosa, E., Iley, J. (1992). The microsomal demethylation of N,N-dimethylbenzamides - substituent and kinetic deuterium-isotope effects. Biochem. Pharmacol. 44:651-658.
3. Crivori, P., Poggesi, I. (2006). Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs. Eur J Med Chem. 41:795-808.
4. Daly, A. K. (2006). Significance of the minor cytochrome P450 3A isoforms. Clin. Pharmacokinet. 45:13-31.
5. Danielson, P. B. (2002). The cytochrome P450 superfamily: Biochemistry, evolution and drug metabolism in humans. Curr. Drug Metab. 3:561-597.
6. Dinnocenzo, J. P., Karki, S. B., Jones, J. P. (1993). On isotope effects for the cytochrome-P-450 oxidation of substituted N,N-dimethylanilines. J. Amer. Chem. Soc. 115:7111-7116.
7. Ekins, S., Bravi, G., Wikel, J. H., Wrighton, S. A. (1999). Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J. Pharmacol Exp Ther. 291:424-433.
8. Ekins, S., Wrighton, S. A. (1999). The role of CYP2B6 in human xenobiotic metabolism. Drug Metab. Rev. 31:719-754.
9. Ekins, S., de Groot, M. J., Jones, J. P. (2001). Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites. Drug Metab. Dispos. 29:936-944.
10. Ekins, S., Stresser, D. M., Williams, J. A. (2003). In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol. Sci. 24:161-166.
11. Fontana, E., Dansette, P. M., Poli, S. M. (2005). Cytochrome P450 enzymes mechanism based inhibitors: Common sub-structures and reactivity. Curr. Drug Metab. 6:413-454.
12. Fukami, T., Nakajima, M., Sakai, H., Katoh, M., Yokoi, T. (2007). CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin, and theophylline. Drug Metab. Dispos. 35:335-339.
13. Garfinkel, D. (1958). Studies on pig liver microsomes I. Enzymic and pigment composition of different microsomal fractions. Arch. Biochem. Biophys. 77:493-509.
14. Groves, J. T. (1985). Key elements of the chemistry of cytochrome P-450. The oxygen rebound mechanism. J. Chem. Educat. 62:928-931.
15. Guengerich, F. P., Shimada, T. (1991). Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 4:391-404.
16. Guengerich, F. P. (2001). Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 14:611-641.
17. Guengerich, F. P. (2003). Cytochromes P450, drugs, and diseases. Mol Interv. 3:194-204.
18. Guengerich, F. P. (2005). Human cytochrome P450 enzymes. In P. R. Ortiz de Montellano (ed.), Cytochrome P450: Structure, Mechanism and Biochemistry (pp. 377-530). New York: Kluwer Academic/Plenum.
19. Gund, P. (1977). Three-dimensional pharmacophoric pattern searching. Prog. Mol. Subcell. Biol. 5:117-143.
20. Hall, L. R., Hanzlik, R. P. (1990). Kinetic deuterium-isotope effects on the N-demethylation of tertiary amides by cytochrome-P-450. J. Biol. Chem. 265:12349-12355.
21. Hansch, C., Mekapati, S. B., Kurup, A., Verma, R. P. (2004). QSAR of cytochrome P450. Drug Metab. Rev. 36:105-156.
22. He, X. Y., Tang, L., Wang, S. L., Cai, Q. S., Wang, J. S., Hong, J. Y. (2006). Efficient activation of aflatoxin B1 by cytochrome P450 2A13, an enzyme predominantly expressed in human respiratory tract. Int. J. Cancer 118:2665-2671.
23. Isin, E. M., Guengerich, F. P. (2007). Complex reactions catalyzed by cytochrome P450 enzymes. Biochim. Biophys. Acta-Gen. Subj. 1770:314-329.
24. Karki, S. B., Dinnocenzo, J. P., Jones, J. P., Korzekwa, K. R. (1995). Mechanism of oxidative amine dealkylation of substituted N,N-dimethylanilines by cytochrome P-450: application of isotope effect profiles. Journal of the American Chemical Society. 117:3657-3657.
25. Klingenberg, M. (1958). Pigments of rat liver microsomes. Arch. Biochem. Biophys. 75:376-386.
26. Lee, H., Yeom, H., Kim, Y. G., Yoon, C. N., Jin, C., Choi, J. S., Kim, B., Kim, D. (1998). Structure-related inhibition of human hepatic caffeine N3-demethylation by naturally occurring flavonoids. Biochem. Pharmacol. 55:1369-1375.
27. Lewis, D. F. V. (2001). Guide to Cytochromes P450: Structure and Function. London: Taylor and Francis.
28. Lewis, D. F. V. (2003). Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xenobiotics: A compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. Curr. Med. Chem. 10:1955-1972.
29. Lewis, D. F. V. (2004). 57 varieties: The human cytochromes P450. Pharmacogenetics 5:305-318.
30. Locuson, C. W., Wahlstrom, J. L. (2005). Three-dimensional quantitative structure-activity relationship analysis of cytochromes P450: Effect of incorporating higher-affinity ligands and potential new applications. Drug Metab. Dispos. 33:873-878.
31. Mansuy, D. (1998). The great diversity of reactions catalyzed by cytochromes P450. Comp. Biochem. Phys. C 121:5-14.
32. Meunier, B., De Visser, S. P., Shaik, S. (2004). Mechanism of oxidative reactions catalyzed by cytochrome P450 enzymes. Chem. Rev. 104:3947-3980.
33. Mitsuda, M., Iwasaki, M., Asahi, S. (2006). Cynomolgus monkey cytochrome P4502C43: cDNA cloning, heterologous expression, purification and characterization. J. Biochem. 139:865-872.
34. Nelson, D. L., Cox, M. M. (2005). Mixed-function oxidases, oxygenases and cytochrome P-450. Lehninger Principles of Biochemistry (pp. 798-799). New York: W.H. Freeman and Company.
35. Omiecinski, C. J., Remmel, R. P., Hosagrahara, V. P. (1999). Concise review of the cytochrome P450s and their roles in toxicology. Toxicol. Sci. 48:151-156.
36. Ortiz de Montellano, P. R. (2005). Cytochromes P450: Structure, mechanism and biochemistry. New York: Kluwer Academic/Plenum.
37. Parkinson, A. (2001). Biotransformation of xenobiotics. In C. D. Klaassen (ed.), Casarett and Doull's Toxicology: The Basic Science of Poisons (pp. 172-191). New York: McGraw-Hill.
38. Ridderstrom, M., Zamora, I., Fjellstrom, O., Andersson, T. B. (2001). Analysis of selective regions in the active sites of human cytochromes P450, 2CS, 2C9, 2C18, and 2C19 homology models using GRID/CPCA. J. Med. Chem. 44:4072-4081.
39. Shaik, S., Kumar, D., de Visser, S. P., Altun, A., Thiel, W. (2005). Theoretical perspective on the structure and mechanism of cytochrome P450 enzymes. Chem. Rev. 105:2279-2328.
40. Smith, G., Stubbins, M. J., Harries, L. W., Wolf, C. R. (1998). Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica 28:1129-1165.
41. Tegtmeier, M., Legrum, W. (1994). Approach to detect substrates suitable to measure the coumarin 7-hydroxylase (CYP 2A-5) - Structure-activity- relationships. Archiv. Der Pharmazie 327:299-302.
42. Testa, B. (1995). The metabolism of drugs and other xenobiotics. London: Academic Press Limited.
43. Von Weymarn, L. B., Murphy, S. E. (2003). CYP2A13-catalysed coumarin metabolism: Comparison with CYP2A5 and CYP2A6. Xenobiotica 33:73-81.
44. Wang, Y. H., Han, K. L., Yang, S. L., Yang, L. (2004). Structural determinants of steroids for cytochrome P450 3A4-mediated metabolism. Theochem-J. Mol. Struct. 710:215-221.
45. Williams, J. A., Ring, B. J., Cantrell, V. E., Jones, D. R., Eckstein, J., Ruterbories, K., Hamman, M. A., Hall, S. D., Wrighton, S. A. (2002). Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab. Dispos. 30:883-891.